Norway-based clinical-stage biotechnology company Ultimovacs (OSE:ULTI) announced on Monday that it has secured Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) for its UV1 cancer vaccine in mesothelioma, supported by positive results from the NIPU Phase II trial.
UV1 has also received ODD from the US Food and Drug Administration (FDA) for treating mesothelioma and malignant melanoma stages IIB to IV.
In the EU, ODD provides exclusive market rights for 10 years, clinical protocol assistance, centralised marketing authorisation and reduced regulatory fees.
Mesothelioma, often linked to asbestos exposure, lacks effective treatments, making UV1's approval significant. The NIPU trial demonstrated UV1's efficacy in combination with ipilimumab and nivolumab, showing improved overall survival without added toxicities.
Recently approved Fast Track designation from the FDA further accelerates UV1's path to approval, marking potentially significant progress in mesothelioma treatment.
Pierre Fabre Pharmaceuticals reports FDA acceptance and Priority Review of Tabelecleucel BLA
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Hyperfine secures FDA clearance for faster brain imaging software
Silo Pharma agrees Alzheimer's drug licence
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Camurus reports positive Phase 3 ACROINNOVA 2 results
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI